Novo Nordisk on November 11 announced steep price cut in its obesity drug Wegovy by up to 37 percent in India as it aims to expand access to chronic weight management therapy and take on rival weight loss drug Mounjaro.
The company announced that the starting dose of Wegovy (0.25 mg) will now cost Rs 2,712 per week, down from Rs 4,336—a move that significantly lowers the entry barrier for patients prescribed the once-weekly injectable.
Prices across all five dose strengths have been revised, with the highest dose (2.4 mg) now priced at Rs 4,100 per week.
Wegovy has already become slightly cheaper after GST rate was slashed from 12 percent to 5 percent in September 2025.
Novo Nordisk's price cut of Wegovy follows the company's partnership with Emcure Pharmaceuticals to commercialize Poviztra, a second brand of Wegovy. Novo plans to utilise Emcure's distribution network to expand access beyond metro and tier-2 cities.
The Danish drugmaker Novo Nordisk is shifting gears as it takes on rival brand Eli Lilly's Mounjaro, which has emerged as the number one brand by value in Indian pharmaceutical market in October. The company may face potential entry of generic competitors in the first half of next year, which will further pose challenges.
“This price revision underlines our mission to provide quality obesity treatment to Indians which is effective, safe, convenient and can be sustained in their daily lives,” said Vikrant Shrotriya, managing director of Novo Nordisk India.
“We’ve listened to our patient and doctor communities and acted in their interest,” Shrotriya.
Wegovy, launched in India in June 2025, is the first and only drug approved for both chronic weight management and cardiovascular risk reduction in people with obesity or overweight. Wegovy is shown to have more than 20 percent weight loss in up to 1 in 3 individuals when used along with lifestyle modifications.
The drug is delivered via the company’s FlexTouch pen device, in five dose strengths - 0.25 mg, 0.5 mg, 1 mg, 1.7 mg & 2.4 mg - allowing gradual dose escalation and personalized treatment. The pricing overhaul comes amid growing demand for evidence-based obesity therapies and increased competition in India’s weight-loss drug market.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
